Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model
Source: MDLinx, November 2020
Since patients with stage I/IIA cutaneous melanoma (CM) are currently not eligible for adjuvant therapies despite relapse risk uncertainty, researchers examined the ability of a recently developed model that combines clinicopathologic and gene expression variables (CP-GEP) to identify patients with stage I/IIA melanoma who have a high risk for disease relapse.
